GlaxoSmithKline bows out of Ebola vaccine development

Despite an ongoing Ebola outbreak in the Democratic Republic of Congo, GlaxoSmithKline is giving up efforts to develop three vaccines to combat the virus. It will transfer rights to its work to the Sabin Vaccine Institute in the U.S. 

Advertisement

Under the transfer agreement, Sabin has exclusively licensed the technology and acquired patent rights of the potential vaccines. 

GSK completed the handover for free, and the National Institutes of Health vaccine research group is stepping in to help with development efforts. 

While Ebola is a deadly and highly contagious disease, it is also relatively rare, which makes the potential vaccine market sporadic and likely unprofitable, according to Reuters. 

More articles on pharmacy:
Average chief pharmacy officer salary by state
2020 election brewing ‘perfect storm’ for drug-pricing reform, analyst says
Colombia fines Pfizer $25K for drug price inflation

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.